Newsletter

Menu

Celgene posts upbeat Q4 results, guidance

By Staff Correspondent |

Celgene Corp. (CELG) swung to a profit in the fourth quarter from a loss last year, helped by lower research and development costs as well as a decline in acquisition-related charges and restructuring. A drop in income tax provision also contributed to the bottom line growth. The results exceeded analysts’ expectations. The pharma giant also guided full-year 2019 earnings and revenue above consensus estimates.

Net income was $1.07 billion or $1.50 per share compared to a loss of $81 million or $0.10 per share in the previous year quarter. Adjusted earnings grew 20% to $2.39.

Total revenue increased 16% to $4.04 billion. The results were benefited by increases in treatment duration and market share for multiple myeloma.

Looking ahead into the full year 2019, the company expects total revenue in the range of $17 billion to $17.2 billion and earnings in the range of $8.40 to $9.08 per share. Adjusted earnings are anticipated to be in the range of $10.60 to $10.80 per share.

Celgene fourth quarter 2018 earnings snapshot
Celgene Q4 2018 Earnings Infographic

The company expects Revlimid product sales to be about $10.8 billion, Pomalyst/Imnovid product sales of about $2.4 billion, Otezla product sales of about $1.9 billion, and Abraxane product sales of about $1.1 billion. Operating margin is predicted to be about 49% and adjusted operating margin is projected to be about 57.5%.

For the fourth quarter, Revlimid sales increased 16% driven by increases in treatment duration and market share. Pomalyst/Imnovid sales jumped 28% on higher treatment duration and market share. Otezla sales climbed 21% on increases in demand as well as launch uptake in key ex-US markets, including Japan. Abraxane sales rose 7% driven primarily by demand.

Also read: Transcript of Celgene fourth quarter 2018 earnings call

In January, Celgene and Bristol-Myers Squibb (BMY) have entered into a definitive merger agreement whereby Bristol-Myers will acquire Celgene for about $74 billion. The transaction is expected to close in the third quarter of 2019.

Shares of Celgene ended Wednesday’s regular session up 0.58% at $88.06 on the Nasdaq. Following the earnings release, the stock inched up 0.36% in the premarket session.

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Advertisement

More on this Company

stock market

US stocks plummet to the worst since 2008 crisis amid coronavirus outbreak

February 28, 2020

Lyft (LYFT) stock shows signs of recovery amid pricing concerns

December 13, 2019
Earnings Update by AlphaStreet

Five Below (NASDAQ: FIVE): Q3 2019 Earnings Snapshot

December 4, 2019

339 responses to “Celgene posts upbeat Q4 results, guidance”

  2. Leandro Farland

    […]Wonderful story, reckoned we could combine a few unrelated data, nevertheless seriously really worth taking a search, whoa did one particular learn about Mid East has got extra problerms at the same time […]

  17. Click Here

    […]Wonderful story, reckoned we could combine several unrelated information, nonetheless seriously really worth taking a appear, whoa did 1 master about Mid East has got far more problerms too […]

  45. Click Here

    […]Wonderful story, reckoned we could combine several unrelated data, nonetheless genuinely worth taking a search, whoa did one particular understand about Mid East has got much more problerms at the same time […]

  66. Click Here

    […]Wonderful story, reckoned we could combine a number of unrelated data, nevertheless actually worth taking a search, whoa did one study about Mid East has got additional problerms at the same time […]

  118. العقاقير

    […]we prefer to honor many other world-wide-web internet sites on the internet, even if they aren’t linked to us, by linking to them. Underneath are some webpages really worth checking out[…]

  147. Refereed articles

    […]Wonderful story, reckoned we could combine a couple of unrelated information, nonetheless really really worth taking a look, whoa did a single learn about Mid East has got a lot more problerms at the same time […]

  165. Fiverr Earn

    […]Wonderful story, reckoned we could combine a handful of unrelated data, nevertheless actually worth taking a look, whoa did one particular discover about Mid East has got more problerms also […]

  284. Fanuc

    […]we prefer to honor several other world wide web internet sites around the internet, even if they aren’t linked to us, by linking to them. Underneath are some webpages really worth checking out[…]

  290. nft

    […]although web-sites we backlink to below are considerably not related to ours, we really feel they may be really really worth a go through, so have a look[…]

  313. french bulldog

    […]Wonderful story, reckoned we could combine a number of unrelated data, nonetheless seriously really worth taking a appear, whoa did one particular learn about Mid East has got far more problerms as well […]

Leave a Reply

Top